Shares of Amarin Corporation PLC (NASDAQ:AMRN) increased 3.1% in premarket trading after the company presented new in vitro data at the European Society of Cardiology Congress 2025 showing potential anti-inflammatory mechanisms of its drug VASCEPA/VAZKEPA.
The research highlighted how eicosapentaenoic acid (EPA), VASCEPA’s active ingredient, may help reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) by modulating the NLRP3 inflammasome in monocyte-derived macrophages. The findings also demonstrated EPA’s potential to inhibit lipoprotein(a) oxidation, decrease oxidative stress, and lower pro-inflammatory protein expression in endothelial cells.
“These in vitro analyses provide additional insight into the mechanisms of action for VASCEPA/VAZKEPA, including the potential effect of reducing inflammation in atherosclerotic cardiovascular disease as well as its reported impact on reducing cardiovascular events in at-risk patients with elevated Lp(a),” said Steven Ketchum, EVP, President of R&D, and Chief Scientific Officer at Amarin.
Preliminary results indicate that EPA may reduce extracellular ATP release and caspase 1 activation in stimulated monocyte-derived macrophages from individuals both with and without ASCVD, suggesting a protective effect against inflammation through modulation of the ATP-P2X7 axis.
Professor Kelvin Lee, Consultant Interventional Cardiologist and Director of the Cardiovascular Research Program at United Lincolnshire Hospitals NHS Trust, commented that the data implies EPA’s benefits may go beyond triglyceride reduction, potentially affecting autophagy and inflammasome activity in ways that could lower cardiovascular risk.
Amarin Corporation stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.